Lana Pine is the editor of HCPLive Rheumatology. She is an experienced editor and technical writer with a demonstrated history of working in the banking and publishing industries. In her free time, she enjoys cooking, yoga, listening to podcasts, and drawing. She can be reached via email at LPine@mjhlifesciences.com.
Andrew L Concoff, MD, FACR, CAQSM: Value-Based Care
June 29th 2021Rheumatology Network sat down with Andrew L Concoff MD, FACR, CAQSM, to discuss value-based care, including the benefits, collaborate approach to working with payers, the revenue and cost savings, and how value-based care can support routine and consistent health visits.
Read More
Serum Protein Biomarker Panel Differentiates Between Psoriatic Arthritis and Rheumatoid Arthritis
June 24th 2021In patients with early inflammatory arthritis, a serum protein biomarker panel was proven effective in separating patients with psoriatic arthritis from those with rheumatoid arthritis.
Read More
Guidelines for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic
June 23rd 2021The American College of Rheumatology has updated its treatment guidelines for the management of pediatric rheumatic disease during the COVID-19 pandemic. The guideline includes 33 final guidance recommendations, 8 of which received moderate-to-high task force consensus.
Read More
Upadacitinib Effectively Treats Patients With Psoriatic Arthritis and Axial Involvement
June 22nd 2021Upadacitinib (UPA) effectively treated patients with psoriatic arthritis (PsA) and axial involvement, a group that is historically more likely to have higher disease burden and more quality-of-life impairments than patients without axial involvement.
Read More
Safety and Efficacy of Secukinumab for Juvenile Idiopathic Arthritis
June 21st 2021Rheumatology Network interviewed Hermine Brunner, MD, MSc, MBA, lead investigator of the JUNIPERA study, which reported on the safety and efficacy of secukinumab for patients with juvenile idiopathic arthritis (JIA), presented at the EULAR 2021 Virtual Congress. Secukinumab was the first approved biologic for specific JIA categories in the US and marked improvement of skin involvement with juvenile spondyloarthritis (jPSA) and increased quality of life for children with chronic arthritis plus psoriasis.
Read More
Alexis Ogdie, MD: Importance of Patient Experience in Psoriatic Arthritis Treatment
June 14th 2021In partnership with CreakyJoints, Alexis Ogdie, MD discusses her study, “Real-World Patient Experience and Treatment Preferences in Patients With Psoriatic Arthritis,” which was recently presented at the EULAR 2021 Virtual Congress.
Read More
Liana Fraenkel, MD, MPH: ACR 2021 Treatment Guidelines for Rheumatoid Arthritis
June 11th 2021Liana Fraenkel, MD, MPH, discusses the recent updates to the American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis, for which she served as part of the Core Leadership Team.
Read More
Risankizumab Significantly More Effective Than Placebo in Treating Psoriatic Arthritis
June 10th 2021Risankizumab showed significantly greater improvements in symptoms of psoriatic arthritis when compared with a placebo and was well tolerated in patients who were intolerant to biologics and conventional synthetic disease-modifying antirheumatic drugs.
Read More
Eugen Feist, MD: Olokizumab Emerges as Promising Therapy for Rheumatoid Arthritis
June 10th 2021Rheumatology Network sat down with Eugen Feist, MD, to discuss the recent olokizumab data including the therapeutic prospects for olokizumab, its unique biologic mode of action, and the clinical significance of the phase III studies.
Read More
Jessica Walsh, MD: Patient Perspectives of Biologic Treatments for Axial Spondyloarthritis
June 9th 2021Rheumatology Network spoke with Jessica Walsh, MD, to discuss her study, “Patient perspectives of biologic treatments for axial spondyloarthritis: satisfaction, wear-off between doses, and use of supplemental medications."
Read More
Alyssa Johnsen, MD, PhD, spoke with Rheumatology Network about the efficacy of guselkumab for psoriatic arthritis, the challenges of delivering safe and effective treatments in this patient population, and how guselkumab can help improve physical, social, and work activity for these patients.
Read More
Benjamin Nowell, PhD: Mindfulness Program for Patients With Rheumatic Disease
June 8th 2021Rheumatology Network sat down for an interview with Benjamin Nowell, PhD, in partnership with CreakyJoints, to discuss the Healthy Mind Healthy You study, which assessed 2 mindfulness programs of varying lengths, designed for people with rheumatic disease, and compared the results.
Read More
Roy Fleischmann, MD: Efficacy of Upadacitinib and Adalimumab for Rheumatoid Arthritis
June 4th 2021Roy Fleischmann, MD, discusses his presentations for EULAR 2021, which include topics about the side effects of JAK inhibitors, disease activity measures of methotrexate withdrawal among patients with rheumatoid arthritis, and the long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis.
Read More
Neil Solomons, MD: Efficacy of Voclosporin for Treatment of Lupus Nephritis
June 3rd 2021Neil Solomons, MD, sits down to discuss his latest study, entitled “Aurinia Announces Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS™ (voclosporin) in The Lancet,” which will be presented at EULAR 2021.
Read More
John Botson, MD, RPh, CCD: Pegloticase Efficacy and Safety in Patients With Gout
June 2nd 2021As a part of our EULAR 2021 coverage, Rheumatology Network sat down with John Botson, MD, RPh, CCD, to discuss why patients with uncontrolled gout are significantly burdened with systemic co-morbid disease, why gout is more prevalent and severe in patients who have received kidney transplants, and why such few studies have been published on the use of pegloticase in organ transplant patients.
Read More
Laura Coates, MBChB, MRCP, PhD: What Factors Influence Patients' Opinion of Remission?
May 31st 2021Rheumatology Network interviewed Laura Coates, MBChB, MRCP, PhD, to discuss what her recent study adds to existing psoriatic arthritis (PsA) research, what some of the key factors are that impact a patient’s opinion of remission, and the clinical significance.
Read More